Glycogen synthase kinase-3 inhibition by 3-anilino-4-phenylmaleimides: insights from 3D-QSAR and docking.
Glycogen synthase kinase-3, a serine/threonine kinase, has been implicated in a wide variety of pathological conditions such as diabetes, Alzheimer's disease, stroke, bipolar disorder, malaria and cancer. Herein we report 3D-QSAR analyses using CoMFA and CoMSIA and molecular docking studies on 3-anilino-4-phenylmaleimides as GSK-3alpha inhibitors, in order to better understand the mechanism of action and structure-activity relationship of these compounds. Comparison of the active site residues of GSK-3alpha and GSK-3beta isoforms shows that all the key amino acids involved in polar interactions with the maleimides for the beta isoform are the same in the alpha isoform, except that Asp133 in the beta isoform is replaced by Glu196 in the alpha isoform. We prepared a homology model for GSK-3alpha, and showed that the change from Asp to Glu should not affect maleimide binding significantly. Docking studies revealed the binding poses of three subclasses of these ligands, namely anilino, N-methylanilino and indoline derivatives, within the active site of the beta isoform, and helped to explain the difference in their inhibitory activity.
Prasanna
Sivaprakasam
S
Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, MS 38677-1848, USA.
Daga
Pankaj R
PR
Xie
Aihua
A
Doerksen
Robert J
RJ
D019943:Amino Acid Substitution; D020134:Catalytic Domain; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000235:genetics; D006860:Hydrogen Bonding; D008301:Maleimides / Q000494:pharmacology*; D008958:Models, Molecular; D011485:Protein Binding / Q000187:drug effects; D020033:Protein Isoforms / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000235:genetics; D021281:Quantitative Structure-Activity Relationship
D008301:Maleimides; D020033:Protein Isoforms; D038362:Glycogen Synthase Kinase 3; C448021:glycogen synthase kinase 3 alpha